+ Intercell

Fast Company's The Futurist tipped us off to this innovative approach to vaccination. Intercell, with the help of IDEO, are developing a needle-free vaccination patch that triggers an immune response through cells in the skin. Intercell's first product targets traveler's diarrhea and could generate around $750 million in revenue. Long term, the product can be mailed directly to consumers for self-application during vaccination campaigns.

This product reminds us a little bit of a concept we created a few months back. We're excited that Intercell is making these patches a reality.